IBTA e-News April 2016 out now

By 30th April 2016 May 17th, 2016 IBTA News
[30 April 2016] The IBTA's monthly e-News has now been released and has been emailed to all subscribers.

Some of the highlights from the April issue include:

  • Several leading figures in brain tumour research and care have been appointed to the US Government's newly established 'Moonshot Initiative' to advance cancer research
  • In recently published guidance, the European Medicine's Agency (EMA) has acknowledged the need to bring patients' perspectives of their treatments and illness into future cancer research
  • Following a successful e-Petition calling for a UK Parliamentary debate on brain tumour research funding, Health Minister George Freeman MP has announced a package of measures to improve brain tumour research, diagnosis and treatment.a package of measures has been announced
  • A study has found that glioma patients fare better when given a combination of radiotherapy and chemotherapy, as opposed to radiotherapy alone
  • Both regular aspirin use and childhood chickenpox infection have been linked to a lower risk for glioma
  • The blood pressure medicine prazosin has been found to reduce glioblastoma growth
  • DelMar Pharmaceutical’s experimental VAL-083 treatment for glioblastoma is due to progress to phase III clinical trials

You can read the IBTA e-News April edition online here.

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News by registering here.

To see an archive of existing e-News issues, click here.


let us know you agree to cookies

The IBTA website uses cookies to give you the best online experience in accordance with our cookies policy. If you are happy, please confirm by clicking the 'Accept' button below.